Inactive Instrument

Other languages Celldex Therapeutics, Inc. Nasdaq

Equities

US15117B1035

Other languages

Unlock all the news: Be the first to know and act before the market!

Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation	09:31am
Celldex Therapeutics Insider Sold Shares Worth $1,586,844, According to a Recent SEC Filing	06-11
Celldex Therapeutics Insider Sold Shares Worth $525,873, According to a Recent SEC Filing	06-11
Celldex Therapeutics Insider Sold Shares Worth $1,579,353, According to a Recent SEC Filing	06-05
Celldex Therapeutics Insider Sold Shares Worth $1,964,088, According to a Recent SEC Filing	06-05
Celldex Therapeutics Insider Sold Shares Worth $1,191,775, According to a Recent SEC Filing	06-03
Celldex Therapeutics Insider Sold Shares Worth $1,319,156, According to a Recent SEC Filing	06-03
Celldex Therapeutics Insider Sold Shares Worth $1,298,384, According to a Recent SEC Filing	06-03
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria At Eaaci 2024	06-02
Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study	05-15
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis	05-15
Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	04-17
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering	02-28
Sector Update: Health Care Stocks Weaker Monday Afternoon	02-26
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates	02-26
Sector Update: Health Care Stocks Mixed Premarket Monday	02-26
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell	02-26
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-26
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-26

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Celldex Therapeutics, Inc. Nasdaq

Equities

US15117B1035

Other languages

Filters